Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine versus placebo and paroxetine for cognitive dysfunction in working patients with major depressive disorder
2014-000230-34Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) and cognitive impairment associated with major depressive disorder (CIAMD) (3 arms), sponsored by Lundbeck. Primary endpoint: Change in Digit Symbol Substitution Test (DSST). Started Aug 2014; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)cognitive impairment associated with major depressive disorder (CIAMD)
Beyond the preview
Go deeper on 2014-000230-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000230-34.